Skip to main content
Support Quality Journalism.
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just
$1.99
per week
for first 24 weeks
Enjoy unlimited digital access
START TODAY
Get full access to globeandmail.com
Just $1.99 per week
for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
The Globe and Mail
Member Benefits
Subscribe
Subscribe
Register
Log in
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
My account
Following
Bookmarks
Reading history
Newsletters
Subscriptions
Settings
Help
AdChoices
Canada
World
Business
Investing
Opinion
Politics
Sports
Life
Arts
Drive
Real Estate
Watchlist
Search
Search
Quick links
Horoscopes
Puzzles
Member Benefits
Newsletters
Globe Shop
Investigations
Death Notices (Legacy.com)
Reader services
Subscribe
Following
Subscriptions
Settings
Customer Help
Contact us
Log in
Log out
Pharmaceutical industry
Follow
Latest
opinion
Why is Justin Trudeau cutting off his nose to spite Big Pharma?
Konrad Yakabuski
February 25
Updated
international business
McKinsey’s top executive voted out as consulting firm faces reckoning over opioid crisis
February 24
Updated
report on business
Bausch Health shareholder pushes for completion of eye-care spinoff by end of 2021
February 12
Updated
european business
GSK forecasts dip in profit but says plan to split business still on track
February 3
Updated
report on business
Investors flock to Canadian device maker Sernova hoping to transform how diabetes is treated
January 21
Updated
report on business
Bausch Health expects 2020 revenue to exceed previous guidance
January 13
Updated
More Stories Below Advertisement
politics
Regulations to lower drug prices in Canada delayed yet again after industry cites COVID-19 concerns
December 30
Updated
u.s. business
Merck signs $356-million U.S. supply deal for experimental COVID-19 treatment
December 23
Updated
report on business
Canopy Growth cuts ties with investment company Canopy Rivers
December 21
Updated
alberta
Newly approved treatment could save a young child in Edmonton with a rare disease. It costs $2.8-million per dose
December 19
Updated
u.s. business
Merck sells stake in vaccine developer Moderna
December 2
Updated
canada
Ottawa blocks Trump plan to allow bulk U.S. import of cheaper prescription drugs from Canada
November 29
Updated
opinion
The credibility of pharmaceutical companies is on the line. Will they get it right?
Jillian Kohler
and
Jonathan Cushing
November 24
Updated
u.s. politics
Trump makes late-term bid to lower prescription drug costs
November 20
Updated
report on business
Pharmaceutical industry offers Ottawa $1-billion to scrap pending drug pricing rules, documents show
November 15
Updated
report on business
Developing a coronavirus vaccine is just the first step – distribution presents a whole new challenge
November 10
Updated
More Stories Below Advertisement
u.s. business
Cardinal Health and AmerisourceBergen book billions in costs related to opioid lawsuits
November 5
Updated
u.s. business
McKesson says cost of opioid settlements could reach $21-billion
November 3
Updated
international business
Britain starts accelerated review for AstraZeneca’s potential COVID-19 vaccine
November 1
Updated
u.s. business
U.S. to charge Teva with conspiring to raise prices of generic drugs, sources say
August 25
Updated
u.s. business
Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion
August 19
Updated
u.s. business
U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation
August 18
Updated
world
Chairman of China’s Sinopharm rules out high price for potential coronavirus vaccine
August 18
Updated
international business
Taro Pharmaceuticals to pay more than $200-million to settle U.S. probe over fixing prices of generic drugs
July 23
Updated
u.s. business
Gilead begins testing inhalable form of remdisivir for treating COVID-19
July 8
Updated
european business
EU secures potential COVID-19 drugs from Roche, Germany’s Merck: source
July 8
Updated
report on business
Bellus stock drops 72% after highly anticipated drug disappoints in human trials
July 6
Updated
u.s. business
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient
June 29
Updated
report on business
Aurora Cannabis to close facilities, lay off 700 workers in restructuring
June 23
Updated
report on business
Repare Therapeutics seeks to raise up to US$152-million in Nasdaq share offering
June 15
Updated
report on business
Lilly says COVID-19 treatment could be authorized for use as soon as September
June 10
Updated
u.s. business
Gilead signs deals with generic drugmakers to scale up COVID-19 drug supply
May 12
Updated
report on business
Canopy Growth says two top executives have left the cannabis firm
May 12
Updated
View More Stories
To view this site properly, enable cookies in your browser. Read our
privacy policy
to learn more.
How to enable cookies